[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370094-105":59,"doc-detail-370094-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","usp7-promotes-chemotherapy-resistance-and-dna-damage-response-through-stabilizing-and-deubiquitinating-kdm4a-in-bladder-cancer","USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer","","Bladder cancer exhibits high recurrence and cisplatin resistance, making it critical to uncover mechanisms that govern treatment response. This study identifies lysine demethylase KDM4A as a clinically relevant factor associated with poor prognosis and supports its pro-proliferative role in bladder cancer cells and models. Co-immunoprecipitation and mass spectrometry show USP7 as an interacting partner of KDM4A, where USP7 deubiquitinates KDM4A to uncouple proteasome-dependent degradation. Positive USP7–KDM4A correlations and functional validations indicate that antagonizing the USP7–KDM4A axis increases cisplatin-induced DNA damage and sensitizes tumors to cisplatin.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/usp7-promotes-chemotherapy-resistance-and-dna-damage-response-through-stabilizing-and-deubiquitinating-kdm4a-in-bladder-cancer/370094/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/usp7-promotes-chemotherapy-resistance-and-dna-damage-response-through-stabilizing-and-deubiquitinating-kdm4a-in-bladder-cancer/370094.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in bladder cancer treatment?","Question",{"text":112,"@type":113},"It addresses the challenge that advanced bladder cancer is insensitive to cisplatin, largely due to cisplatin resistance, and seeks mechanisms that determine responsiveness to cisplatin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are KDM4A and USP7 linked in bladder cancer?",{"text":117,"@type":113},"KDM4A overexpression is associated with poor prognosis, and USP7 is identified as an interacting partner in the KDM4A protein complex. USP7 deubiquitinates KDM4A, which reduces proteasome-dependent degradation.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the functional impact of targeting the USP7–KDM4A axis?",{"text":121,"@type":113},"Cell and animal assays show that antagonizing the USP7–KDM4A axis aggravates cisplatin-induced DNA damage and sensitizes bladder cancer to cisplatin.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370094,1790215697,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nUSP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer  \nHailang Yang 1,5, Xiaoqiang Liu 1,5, Jianqiang Nie2,5, Shuwei Wu1,5, Li Ma3, Yi Jiang4, Lizhi Zhou1, Wen Deng 1, Qianxi Dong 1, Situ Xiong 1, Sheng Li1, Fuchun Zheng 1, An Xie 1 ✉, Songhui Xu1 ✉ and Bin Fu1 ✉  \n© The Author(s) 2025  \n|  |  |  |\n| --- | --- | --- |\n|  | Bladder cancer is a common malignancy, and the insensitivity of advanced bladder cancer to cisplatin poses an imminent challenge to treatment. Our study aims to identify novel targets that mediate cisplatin responsiveness in bladder cancer. Accordingly, overexpression of the histone demethylase KDM4A in clinical cohorts was found in association with poor prognosis. Tissue culture and animal tests showed that KDM4A pis ro-proliferative in bladder cancer cells. Using co-immunoprecipitation and mass spectrometry methods, we identiﬁed that USP7 is an interacting partners in KDM4A protein complex, in which USP7 catalyzes KDM4A proteins deubiquitination that uncouples the proteasome-dependent degradation. In accordance, a positive correlation between USP7 and KDM4A protein expression was noted in bladder cancer clinical samples. Functional validation tests conﬁrmed that USP7 and KDM4A act complementarily to drive bladder cancer cell proliferation. Importantly, cell and animal assays all evidenced that antagonizing the USP7-KDM4A axis would aggravate cisplatin-induced DNA damage and sensitize cisplatin |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| responsiveness. |  |  |\n|  | Cell Death and Disease (2026)17:123; [https://doi.org/10.1038/s41419-025-08297-2](https://doi.org/10.1038/s41419-025-08297-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nBladder cancer ranks among the most prevalent malignancies of the urinary system, exhibiting a striking gender disparity with signiﬁcantly higher incidence in males than females [1] . Histologically, transitional cell carcinoma represents the predominant pathological type, clinically classiﬁed as either muscle-invasive or non-muscle-invasive based on penetration beyond the muscularis propria [2–4] . Early diagnosis is critical for therapeutic outcomes [5], while treatment strategy selection remains a primary challenge for diagnosed patients. Despite diverse therapeutic approaches encompassing surgical resection, chemotherapy, and immunotherapy, the persistently high recurrence rates and platinumbased drug resistance (particularly cisplatin resistance) continue to pose major clinical challenges [2, 6–10]. Consequently, elucidating novel mechanisms to overcome cisplatin resistance has emerged as a research priority.  \nRecent years have witnessed growing interest in protein posttranslational modiﬁcation enzymes (especially demethylases and deubiquitinases) as promising therapeutic targets. Among these, lysine demethylase 4A (KDM4A) and ubiquitin-speciﬁc processing protease 7 (USP7) have been identiﬁed as key regulators in multiple cancer types [11–15] . KDM4A (also termed JMJD2A/ KIA0677/JHDM3A) speciﬁcally removes methyl groups from  \nhistone H3K9me2/3, H3K36me2/3, and H1 .4K26me2/3 modiﬁcations. Accumulating evidence indicates that KDM4A not only participates in fundamental cellular processes like proliferation and migration, but also critically contributes to malignant progression [15, 16] . Cutting-edge research has unveiled multifaceted regulatory mechanisms of KDM4A in solid tumors: in nonsmall cell lung cancer, KDM4A interacts with Stat3 to erase H3K9me3 marks and enhance FGL1 transcription, promoting metastasis [17] . In prostate cancer, SET7/9-mediated KDM4Amethylation drives progression through the NPM3 signaling axis [18], while in oral squamous carcinoma, the LEF1-recruited KDM4A complex suppresses LATS2 expression to facilitate proliferation and inhibit apoptosis [19] . Notably, KDM4A ","cbCaihgVNXj7whYp","https://ap.wps.com/l/cbCaihgVNXj7whYp","pdf",8047768,12,"English","# Introduction\n## Bladder cancer and cisplatin resistance\n## Posttranslational modification enzymes as therapeutic targets\n## Roles of KDM4A in cancer biology\n## Rationale for investigating USP7–KDM4A in bladder cancer","[{\"question\":\"What problem does the study address in bladder cancer treatment?\",\"answer\":\"It addresses the challenge that advanced bladder cancer is insensitive to cisplatin, largely due to cisplatin resistance, and seeks mechanisms that determine responsiveness to cisplatin.\"},{\"question\":\"How are KDM4A and USP7 linked in bladder cancer?\",\"answer\":\"KDM4A overexpression is associated with poor prognosis, and USP7 is identified as an interacting partner in the KDM4A protein complex. USP7 deubiquitinates KDM4A, which reduces proteasome-dependent degradation.\"},{\"question\":\"What is the functional impact of targeting the USP7–KDM4A axis?\",\"answer\":\"Cell and animal assays show that antagonizing the USP7–KDM4A axis aggravates cisplatin-induced DNA damage and sensitizes bladder cancer to cisplatin.\"}]","USP7 promotes chemotherapy resistance and DNA damage response through stabilizing and deubiquitinating KDM4A in bladder cancer | PDF",1790186686,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8fc0223b49e733e50113d01e4a0f291.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78812d11807eabaa28827c9fc5598ae1.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8b708b91da208cb5b288ee82784040e.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f29143193b5b84004b86c51fd66a5f5a.webp",980,1301]